Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance - Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug - Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs - Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs - Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint - Judge tosses Medicare drug negotiation challenges from Bristol Myers Squibb, Johnson & Johnson - Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations - Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss - Bristol Myers Squibb drafts contingency plans for US restrictions on Chinese pharma - Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival